Posted on

Enveric Biosciences to Participate in Upcoming Investor Conferences in March 2022

Enveric Biosciences to Participate in Upcoming Investor Conferences in March 2022

NAPLES, Fla., March 3, 2022 /CNW/ – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a cutting-edge neuroscience company developing next-generation, psychedelic-inspired mental health medicines, today announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in three upcoming investor conferences:

Q1 Virtual Investor Summit
Tuesday, March 8th at 11:45 a.m. ET
To attend, please register here.

Citi’s Psychedelic Drug Call Series
Thursday, March 10th at 10:00 a.m. ET
A fireside chat hosted by Neena Bitritto-Garg, Citi’s Biotech analyst.

Maxim 2022 Virtual Growth Conference
Monday, March 28th – Wednesday, March 30th
To attend, please register here.

For more information about the events, or to schedule a one-on-one meeting with Enveric’s management team, please contact your appropriate Investor Summit Group, Citi, or Maxim representative, respectively, or send an email to KCSA Strategic Communications at EnvericBio@kcsa.com.

About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is a neuroscience-focused pharmaceutical company developing next-generation, psychedelic-inspired mental health medicines. Enveric’s robust pipeline supports drug development from the clinic to commercialization aimed to help millions of patients in need around the world suffering from conditions that include cancer-related distress, PTSD and more. For additional information, please visit www.enveric.com.

Cision View original content:https://www.prnewswire.com/news-releases/enveric-biosciences-to-participate-in-upcoming-investor-conferences-in-march-2022-301494565.html

SOURCE Enveric Biosciences

Posted on

Enveric Biosciences Files Portfolio of Patent Applications for Tryptamine-Based Molecules

Enveric Biosciences Files Portfolio of Patent Applications for Tryptamine-Based Molecules

Robust Portfolio of Psychedelic-Inspired Molecules Positions Enveric to Achieve Global Patent Protection to potentially Cover Millions of Novel Pharmaceutical Candidates

NAPLES, Fla., March 1, 2022 —Enveric Biosciences(NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience-focused pharmaceutical company developing next-generation, psychedelic-inspired mental health medicines, today announces that it has filed its 10th Patent Cooperation Treaty (“PCT”) patent application directed to tryptamine-based derivative molecules, completing the Company’s broad series of PCT applications covering this family of compounds.

The Company’s robust tryptamine-derivative intellectual property portfolio claims novel molecules structurally related to certain naturally occurring psychedelics, such as dimethyltryptamine (DMT), psilocybin, psilocin, and 5-MeO-DMT. Some of the naturally occurring molecules are themselves currently being investigated by researchers around the world as potential treatments for a broad range of psychiatric and neurologic disorders including depression, anxiety, schizophrenia, obsessive-compulsive disorder, posttraumatic stress disorder, eating disorders, pain, autism, and Alzheimer’s disease.1,2

“With the aim of optimizing commercial and regulatory success, a primary focus of Enveric is the creation of novel molecules with improved pharmaceutical characteristics that are also protected by composition of matter, manufacturing, and method-of-use patent claims,” said Dr. Peter Facchini, Chief Innovation Officer, Enveric. “Enveric’s extensive intellectual property portfolio enables the Company to invest in, and harness, the therapeutic potential of these molecules. In our pursuit to maximize the potential of our large and diverse library of novel and protected drug candidates, we intend to pursue out-licensing opportunities to collaborate with other leading drug development companies with a similar focus on delivering benefits to patients suffering from psychiatric and neurologic disorders”.

References:

  1. Szabo A. Psychedelics and immunomodulation: novel approaches and therapeutic opportunities. Frontiers Immunol. 2015;6:358. doi: 10.3389/fimmu.2015.00358
  2. Castelhano J, Lima G, Teixeira M, Soares C, Pais M, Castelo-Branco M. The effects of tryptamine psychedelics in the brain: a meta-analysis of functional and review of molecular imaging studies. Frontiers Pharmacol. 2021;12:739053. doi: 10.3389/fphar.2021.739053

About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is a neuroscience-focused pharmaceutical company developing next-generation, psychedelic-inspired mental health medicines. Enveric’s robust pipeline supports drug development from the clinic to commercialization aimed to help millions of patients in need around the world suffering from conditions that include cancer-related distress, PTSD and more. For additional information, please visit www.enveric.com.

Forward-Looking Statements
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans”, ” expects” or “does not expect”, “proposed”, “is expected”, “budgets”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability to achieve the value creation contemplated by technical developments; the impact of the novel coronavirus (COVID-19) on Enveric’s ongoing and planned pre-clinical or clinical trials; the geographic, social and economic impact of COVID-19 on Enveric’s ability to conduct its business and raise capital in the future when needed; delays in planned pre-clinical or clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; Enveric’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to Enveric’s products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Contacts
Valter Pinto / Allison Soss
KCSA Strategic Communications
212.896.1254 / 212.896.1267
valter@kcsa.com / asoss@kcsa.com

Media Contacts
Natalie Dolphin
Enveric Biosciences Inc.
416.706.6364
ndolphin@enveric.com

Cision View original content:https://www.prnewswire.com/news-releases/enveric-biosciences-files-portfolio-of-patent-applications-for-tryptamine-based-molecules-301492335.html

SOURCE Enveric Biosciences

Posted on

Ai creates new state of consciousness for crime prevention: issue 37

Hello and welcome back.

Happy Fungi Friday 🎉 Whether you swear by the benefits of microdosing or you’re convinced it’s a placebo, get ready for research to confirm your beliefs 🙃

Here’s what’s in store for you in today’s issue:

🍄 The company that’s designing brand new states of consciousness

🍄 Can psilocybin treat the deadliest mental health disorder?

🍄 The effects of different microdosing regimens

🍄 How patients feel 1 year after psilocybin therapy

🍄 And more.

Be sure to check out this week’s Daily Mushroom podcast:

Michael Kydd opens up about the impact of losing his mother at a young age

On this episode of the Daily Mushroom Podcast, we have Michael Kydd, an independent consultant helping psychedelic companies navigate the complex world of government relations. in this emotional episode, Michael talks about his experience with the passing of his mother, and how he believes psychedelics could have strongly benefited his mothers and his family in that difficult time. 

Therapeutic banner

Can psilocybin treat the deadliest mental health disorder?

Anorexia has a higher mortality rate than any other psychiatric condition, as patients have a high risk of death by both suicide and organ failure.

Current treatments work for less than half of patients, which is why Imperial College London is preparing to study psilocybin therapy as an alternative. 

The school is recruiting female patients who have had a diagnosis for at least 3 years and have tried other forms of treatment without success. They’ll each receive 3 doses of psilocybin, and researchers will use several MRIs and EEG scans to understand the effects of the treatment.

Is microdosing a placebo? 💊

This week, Nova Mentis (NOVA) announced that rats with cognitive impairments saw improvements in memory when given a microdose of psilocybin every other day for just two weeks.

However, a new University of Chicago study found no effect on mood or task performance after giving healthy volunteer 4 LSD microdoses 3-4 days apart in a placebo-controlled study.

Could it be that a more frequent dose is needed to see benefits? Or is psilocybin faster acting than LSD? Or maybe microdosing is a placebo after all.

Stay tuned as we follow along with the latest research. 

Depression free for 1 year

Johns Hopkins researchers found that one year after receiving psilocybin therapy, 75% of patients sustained significant reductions in depression scores and 58% no longer qualified for a diagnosis. 

However, about a third of patients also used traditional antidepressants and 42% received additional psychotherapy at some point during the year.

So although psilocybin therapy can have rapid results, multiple treatment options can help sustain the benefits.

Making microdoses even safer

One of the few concerns that experts have about microdosing is the long term impact on heart health. Psilocybin binds to 5-HT2B receptors, which could increase risk of heart valve disease with frequent use. 

Mydecine (MYCO) developed a group of patent-pending molecules that bind only to 5-HT2A receptors, making them safer for microdosing. The company aims to administer these compounds through a microdosing patch to eliminate another side effect: nausea. 

inspirational banner

Shroom use →  less crime

People who use shrooms are less likely to commit crimes, according to new research.

An analysis of The National Survey on Drug Use and Health found that psilocybin use is linked to significantly reduced odds of arrest for:

  • Larceny
  • Burglary & robbery
  • Simple assault & battery
  • Serious violence
  • DUI
  • And other miscellaneous crimes

LSD appeared to have no impact on crime rates 🤔

Brand new states of consciousness

Mindstate Design Labs raised $11.5M in seed funding to create “new novel states of consciousness that just don’t exist yet.”

The company is taking a reverse approach to drug discovery. Researchers will design a unique state of mind first and then create a compound that can get you there. 

How? Using predictive AI technology, subjective data from 7,000+ trip reports, and biochemical data on how different molecules interact with receptors in the body. 

Who’s brave enough to test out a brand new state of mind?

Introducing Houston, your new microdosing companion

Houston is an app that helps you set intentions, track doses and moods, dose with community, and more, on your journey through inner space.

“Took a dive into Houston just now and WOW, absolutely phenomenal. User friendly, knocks out everything I journal while I’m microdosing, love intention section and the playlists. Wow. I am beyond elated you found me,” says one user.

Download Houston on the App Store and follow their Instagram to see when they launch on Android.

Get a Master’s in mushrooms

Vancouver Island University is launching a psychedelic-assisted therapy graduate certificate program this September, becoming the first accredited school in Canada to offer such a program.

A company called Fluence will also be scaling psychedelic training for therapists in Oregon after completing a $3M seed funding round this week.

business banner

Entheon Biomedical (ENBI) initiated a ketamine study on depression in partnership with Wavepaths. It will monitor brain activity with EEG while assessing the impact of Wavepaths’ personalized music technology. 

Field Trip Health (FTRP) reported Q3 financial highlights including $74.5M in cash and patient services revenues of $1.36M, up more than 50% from Q2 and 330% year over year.

PharmaTher (PHRM) was granted a US patent for its formulation of ketamine and betaine anhydrous, a chemical that occurs naturally in the human body and may increase ketamine’s antidepressant effect. The formulation is already patented in Japan and Taiwan, and the company expects to receive patents in Europe, Canada, Israel and China in the near future.

Enveric Biosciences (ENVB) will partner with the University of Calgary to study oral psilocybin for cancer-related distress. Patient enrollment will begin by the end of this year or early next year.

legal banner

Here’s what you missed:

  • Hawaii senators unanimously passed a bill to create a psilocybin research task force and develop a long-term strategy to make treatments accessible and affordable. Read more…
  • With a 7-2 vote, Oklahoma legislators approved a bill in committee to decriminalize low-level possession of psilocybin and promote therapeutic research. Read more…

Video of the Week

Before & After Eating Magic Mushrooms to stop my Tremors

Playlist of the Week

LSD Trip | ACID Trip | Peaceful | Trippy
Posted on

Enveric Biosciences and University of Calgary Collaborate on a Groundbreaking Clinical Trial for EVM-101 in Cancer Related Distress

Enveric Biosciences and University of Calgary Collaborate on a Groundbreaking Clinical Trial for EVM-101 in Cancer Related Distress

Enveric Biosciences (ENVB) will partner with the University of Calgary to study oral psilocybin for cancer-related distress. Patient enrollment will begin by the end of this year or early next year.

Enveric Biosciences

PDF of article

Posted on

Enveric Biosciences Announces Closing of $10 Million Public Offering

Enveric Biosciences Announces Closing of $10 Million Public Offering

NAPLES, Fla., Feb. 15, 2022 /CNW/ – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience company developing next-generation, psychedelic-inspired mental health and oncology treatments, today announced the closing of its previously announced underwritten public offering of 20,000,000 shares of its common stock and warrants to purchase up to 20,000,000 shares of its common stock for gross proceeds of approximately $10 million, before deducting underwriting discounts and commissions and other offering expenses. A.G.P./Alliance Global Partners acted as sole book-running manager for the offering. In addition, Enveric granted the underwriter a 45-day option to purchase up to an additional 3,000,000 shares of common stock and/or warrants to purchase up to an additional 3,000,000 shares of common stock at the public offering price, which the underwriter has partially exercised for warrants to purchase up to 3,000,000 shares of common stock.

All the securities being sold in the offering were offered by Enveric. At closing, Enveric received net proceeds from the offering of approximately $9.2 million, after deducting underwriting discounts and commissions and estimated offering expenses. The Company intends to use the net proceeds from this offering for working capital and to fund other general corporate purposes.

This offering was made pursuant to an effective shelf registration statement on Form S-3 (No. 333-257690) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) that was declared effective by the SEC on July 9, 2021, and to a prospectus supplement and accompanying prospectus. The final prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC and are available on the SEC’s website located at http://www.sec.gov. Electronic copies of the final prospectus supplement may be also obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022 or via telephone at 212-624-2060 or email: prospectus@allianceg.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Enveric Biosciences

Enveric Biosciences (NASDAQ: ENVB) is an innovative biotechnology company developing next-generation mental health and oncology treatments and clinical discovery platform, leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body. Enveric’s robust pipeline supports drug discovery efforts and clinical development programs to enable the potential commercialization of effective treatments for millions of patients in need around the world. For more information, please visit www.enveric.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are any statements that express the current beliefs and expectations of management, including but not limited to statements related to the intended use of proceeds therefrom and expected clinical development of Enveric’s drug product candidates. Any statements contained herein that do not describe historical facts are forward-looking statements that are subject to risks and uncertainties, market and other conditions, that could cause actual results, performance and achievements to differ materially from those discussed in such forward-looking statements. These and other risks are discussed in Enveric’s filings with the SEC, including, without limitation, its Annual Report on Form 10-K, filed on April 1, 2021, and its periodic reports on Form 10-Q and Current Reports on Form 8-K. Enveric cautions readers not to place undue reliance on any forward-looking statements, which speak only as of the date they were made. Enveric undertakes no obligation to update or revise forward-looking statements, except as otherwise required by law, whether as a result of new information, future events or otherwise.

Cision View original content:https://www.prnewswire.com/news-releases/enveric-biosciences-announces-closing-of-10-million-public-offering-301483022.html

SOURCE Enveric Biosciences

Posted on

MDMA saves marriages ❤️: issue 36

Hello and welcome back.

If you’re heading into Valentine’s Day in a rocky relationship, you’ll want to keep reading to learn how MDMA could bring back your spark. If you’re spending this one alone, we’ll keep you company. Join our new Reddit community to discuss all things psychedelic and connect with the Daily Mushroom Community 🧡

Here’s what’s in store for you in today’s issue:

🍄 How MDMA saved a marriage

🍄 Detoxing with Indigenous wisdom

🍄 Why ketamine eases depression

🍄 And more.

Be sure to check out this week’s Daily Mushroom podcast:

How to get legal access to psychedelic therapy

In this episode of the Daily Mushroom Podcast, we have the wonderful Holly Bennett, Communications Director at TheraPsil. Holly dives into how she got started in a rewarding career with psychedelics. She gives us an inside look into how the Section 56 exemption works and some other possible ways Canadians can access psilocybin psychotherapy without it. Holly is very knowledgeable about her field and sheds light on some questions we are sure many people have about Canada’s Special Access Program.

Therapeutic banner

Is this why ketamine helps with depression?

Our brains are constantly making predictions about the world around us based on learned associations – if we hear sirens, we expect to see an ambulance. 

A recent study by University of Wisconsin–Madison researchers found that ketamine blocks the chemical signals that allow us to make predictions.

Why is this beneficial?

Many disorders are rooted in poor predictions. For instance, patients with depression often predict that the worst case scenario is bound to happen. 

“Blocking the negative predictions that are prominent in depressed patients could be how ketamine helps,” explains the school’s psychology and neuroscience professor.

Take a DMT trip without the anxiety

A wild DMT trip that blasts you off to a different dimension has potential to be therapeutic, but also very anxiety-inducing. 

That’s why Cybin (CYBN) developed a version of the molecule that breaks down slowly in the body. So instead of a 10-minute rocket ride to outer space, patients have a smoother, more pleasant experience with a larger therapeutic window. 

The company received a patent for the formulation this week and will study it as a treatment for anxiety disorders in Q3 of this year.

inspirational banner

A dose every six months keeps the divorce lawyer away

A couple was on the verge of getting divorced until they took MDMA together for the first time.

The wife, Ree, said her husband couldn’t open up to her or deal with conflict, but MDMA helped them see eye-to-eye.

“My husband started sharing with me for the first time all these thoughts and emotions,” Ree said. “It was him without the walls.”

They decided to take MDMA together twice a year and go over a list of issues they want to address. Three years later, their marriage is solid and they can communicate openly without the need for drugs.

A better way to measure depression

Diagnosing and measuring depression is usually very subjective, relying on data from patient questionnaires. This leaves room for bias and makes it difficult to know if a treatment is actually working.

MYND Diagnostics of MYND Life Sciences (MYND) developed a biomarker test that provides objective data to solve this problem. It measures inflammation in the brain, which may be what causes depression.

Seeing evidence of improvement gives patients hope in the treatment process, like showing them the “light at the end of the tunnel” as MYND’s CEO explained on a recent Daily Mushroom Podcast.  

The company announced that Monash University will use the biomarker test in a psilocybin study on treatment-resistant depression, which has received $3M in funding from the Australian government. 

Detox with Indigenous wisdom

Universal Ibogaine (IBO) and Osoyoos Indian Band signed an agreement to develop a detox center that combines western science and Indigenous wisdom.

The center will use ibogaine treatments to ease opioid cravings and withdrawal symptoms, followed by Indigenous healing practices as aftercare to “rebuild people in a holistic manner.”

Their flagship detox center will be in Manitoba, Canada with the goal of working with other First Nations to expand across the country, and then globally. 

business banner

Optimi Health (OPTI) received a Dealer’s License from Health Canada and announced that it will begin cultivating, extracting, and processing “the highest-grade all-natural psilocybin in North America” at its facility in Princeton, British Columbia. The facility can secure up to 1,250kg of psilocybin, a value of roughly $53MM CDN.

Ketamine Media launched Psychedelic Therapy Network, a digital platform that connects psychedelic medicine providers with patients seeking treatment across North America.

Cybin (CYBN) announced Q3 financial results and business highlights including C$63.6 million and a C$17.2 million net loss. 

Enveric Biosciences’ (ENBI) stock is 45% off! The share price plummeted this morning after announcing a $10M public offering at 50 cents per share, about 24% below yesterday’s closing price of 66 cents 😬

Ehave, Inc. (EHVVF) acquired Rejuv IV, a company offering at-home ketamine therapy and IV infusions for anything from a hangover to migraines.

legal banner

 Here’s what you missed:

  • The Oregon Health Authority released the first draft of rules for the state’s legal psilocybin program. Only one of 200 species of psilocybin mushrooms will be allowed (psilocybe cubensis, the most popular species) and synthetic psilocybin will be banned. Plus, facilitators will need 120 hours of instruction on psilocybin history, safety, racial justice, and cultural equity. Read more…

  • A bill was filed in Maryland to offer free psychedelic therapy to veterans with PTSD and promote psychedelic research. Read more…
  • Activists in Washington filed an initiative to decriminalize simple drug possession statewide and give $150M in annual funding to substance abuse prevention, recovery, research, and education. The measure could appear on the ballot this November if enough signatures are collected. Read more…
  • Maine lawmakers rejected a bill that would legalize medical use of psilocybin after an 8-3 vote. The bill’s sponsor says she’s not surprised, however “society is changing, and the science is moving quickly, so it’s a matter of when, and not if, legislation like this passes in the future.” Read more…
  •  

Video of the Week

Before & After Eating Magic Mushrooms to stop my Tremors

Playlist of the Week

LSD Trip | ACID Trip | Peaceful | Trippy
Posted on

Enveric Biosciences Announces Successful Synthesis and Filing of Provisional Patent for EV104 – Cannabinoid + Celecoxib Conjugate

Enveric Biosciences Announces Successful Synthesis and Filing of Provisional Patent for EV104 – Cannabinoid + Celecoxib Conjugate

Target Indications include Osteoarthritis and Other Pain Conditions

NAPLES, Fla., Feb. 8, 2022 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience company developing next-generation, psychedelic-inspired mental health, and oncology treatments, today announced the development of EV104a and EV104b, new molecular conjugates for Osteoarthritis (“OA”) and other pain indications.

The treatment paradigm for OA, as reflected in a recent review “Future Directions for the Management of Pain in Osteoarthritis” by Nidhi Sofat, is largely unsatisfactory and based on alleviating pain using NSAIDs and other pharmacotherapies or intra-articular injection of corticosteroids, or hyaluronic acid. Newer therapeutic alternatives, including combination treatments, are needed for optimal control of symptoms. Enveric recently licensed an Innovative Platform technology from Diverse Biotech that led to the successful synthesis of EV104a, and EV104b, two new chemical entity conjugates of cannabidiol (CBD) linked to celecoxib.

EV104a and EV104b are specifically designed to optimize pharmacokinetics and therapeutic synergy via improved delivery, targeting abilities, and potency to potentially be more efficacious and display fewer side effects than current treatments. Enveric has confirmed the stability of the molecules and the robustness of the manufacturing method. Pre-clinical in vitro testing and characterization of these molecules is underway. This program aims to create a new treatment with improved tolerability, decreased toxicity, fewer side effects, and enhanced long-term efficacy.

The EV104 celecoxib-cannabinoid conjugates are protected by a recently filed provisional United States patent application claiming the compositions, methods of synthesis, and methods of treatment for inflammatory medical conditions.

“We are pleased to announce the creation of EV104a and EV104b for the potential treatment of OA and other pain indications. Despite available therapies, individuals with OA continue to suffer and look for new treatments to remediate their pain. As the Company moves forward to execute our clinical development plans, we believe our assets have the potential to demonstrate superior efficacy with a more favorable safety profile compared to current standards of treatment,” said Dr. Joseph Tucker, CEO of Enveric Biosciences.

Osteoarthritis is the most common form of arthritis and a leading cause of disability, resulting in a reduced quality of life. Enveric’s EV104 program entered pre-clinical testing to advance into clinical development with the hope of offering better options for patients living with pain.

About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is an innovative biotechnology company developing next-generation mental health and oncology treatments and clinical discovery platform, leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body. Enveric’s robust pipeline supports drug discovery efforts and clinical development programs to enable the potential commercialization of effective treatments for millions of patients in need around the world. For more information, please visit www.enveric.com.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans,” expects” or “does not expect,” “proposed”, “is expected,” “budgets,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability to achieve the value creation contemplated by technical developments; the impact of the novel coronavirus (COVID-19) on Enveric’s ongoing and planned clinical trials; the geographic, social and economic impact of COVID-19 on Enveric’s ability to conduct its business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; Enveric’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to Enveric’s products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Posted on

Enveric Biosciences to Participate in Upcoming Investor Conferences in February 2022

Enveric Biosciences to Participate in Upcoming Investor Conferences in February 2022

NAPLES, Fla., Jan. 27, 2022 /CNW/ – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, today announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in two upcoming investor conferences:

Citi’s Psychedelic Drug Call Series
Tuesday, February 8th at 10:00 a.m. ET
A fireside chat hosted by Neena Bitritto-Garg, Citi’s Biotech analyst.

Aegis Capital Corp. Virtual Conference
Friday, February 25th at 3:00 p.m. ET
To access the event, please download and import the following iCalendar (.ics) files to your calendar system: Aegis Virtual Conference Calendar.

For more information about the events, or to schedule a one-on-one meeting with Enveric’s management team, please contact your appropriate Citi or Aegis representative, respectively, or send an email to KCSA Strategic Communications at EnvericBio@kcsa.com.

About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is an innovative biotechnology company developing a next-generation mental health and oncology treatment clinical discovery platform, leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body. Enveric’s robust pipeline supports drug development from the clinic to commercialization for millions of patients in need around the world suffering from conditions that include cancer-related distress, PTSD and more. For more information, please visit www.enveric.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/enveric-biosciences-to-participate-in-upcoming-investor-conferences-in-february-2022-301469195.html

SOURCE Enveric Biosciences

Posted on

Enveric Biosciences CEO, Dr. Joseph Tucker, Provides 2021 Year in Review and 2022 Outlook in Letter to Shareholders

Enveric Biosciences CEO, Dr. Joseph Tucker, Provides 2021 Year in Review and 2022 Outlook in Letter to Shareholders

NAPLES, Fla., Jan. 18, 2022 /CNW/ – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-centric biotechnology company, today released a letter to shareholders from Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences.

Dear Enveric Shareholders and Partners:

Reflecting on 2021, I am both extremely impressed with all the accomplishments and progress made and humbled and energized to tackle the opportunities that lie ahead. 2021 was a foundational year that set the stage for our Company by assembling a talented and expert team to execute our strategy for the future. As we move forward in 2022, we find ourselves strategically positioned with a strengthened balance sheet, a deep bench of experienced industry professionals, a platform for new drug discovery, a robust IP portfolio and a growing pipeline of what we believe to be promising drug candidates. We are energized to engage with what I believe will be yet another transformative year for the company.

2021 Year in Review
Enveric launched as a patient-centric biotechnology company, employing innovation and scientific leadership as core principles. Notable highlights from 2021 include:

As of September 30, 2021, we had $21 million in cash, no debt related to loans payable, and working capital of approximately $20 million, enabling us to continue executing on our business plan.

Looking Forward to 2022
The foundation of Enveric’s growth in 2022 will be built upon three pillars: our Drug Development pipeline, Drug Discovery process, and Intellectual Property strategy.

  • Drug Development:
    • Most importantly, our psychedelic-based drug discovery engine is operating in full force to address many targeted unmet needs, starting with the planned execution of a Phase II clinical trial in Cancer Related Distress (CRD), our lead indication, with a 1st generation psychedelic asset, EVM-101.
    • Our second-generation psychedelic-derived suite of products in our Discovery Research is slated to progress towards nominating our lead Development Candidate, EVM-201, and to proceed towards completing a host of CMC (Chemistry Manufacturing and Controls), Pharmacology, and Toxicology experiments, leading to planned INTERACT and Pre-IND meetings with the FDA.
  • Drug Discovery:
    • Design of hundreds of potential lead drug candidates for enriching our second generation and third generation pipeline programs with the aim of progressing towards several future Development Candidate nominations in target undisclosed indications.
    • Focused, enriched and targeted drug discovery engine employing Artificial Intelligence screening to identify top candidates for each program based on drug-like properties, predicted pharmaceutical activity and intellectual property strength.
  • Intellectual Property:
    • Continue to invent new drug candidates and employ internationally filed patent applications to claim the compositions, methods of manufacture, and clinical uses.
    • 12 international Patent Cooperation Treaty (PCT) Patent Applications are expected to publish.
    • 7 Provisional US Patent Applications are expected to be converted to international PCT Patent Applications.
    • 2 additional Provisional US Patent Applications are expected to be filed.

With the new company structure, strengthened by the foundational achievements in 2021 including the assembly of an expert team with the passion and drive for drug development, I am confident in Enveric’s ability to execute on our programs in 2022 and beyond.

On behalf of the Enveric management team and Board of Directors, I thank you for your continued support of the company and I look forward to providing you with further updates as our progress continues.

Sincerely,

Dr. Joseph Tucker,
Chief Executive Officer, Director

About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is an innovative biotechnology company developing next-generation mental health and oncology treatments and clinical discovery platform, leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body. Enveric’s robust pipeline supports drug discovery efforts and clinical development programs to enable potential commercialization of effective treatments for millions of patients in need around the world. For more information, please visit www.enveric.com.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans”, ” expects” or “does not expect”, “proposed”, “is expected”, “budgets”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability to achieve the value creation contemplated by technical developments; the impact of the novel coronavirus (COVID-19) on Enveric’s ongoing and planned clinical trials; the geographic, social and economic impact of COVID-19 on Enveric’s ability to conduct its business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; Enveric’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to Enveric’s products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Cision View original content:https://www.prnewswire.com/news-releases/enveric-biosciences-ceo-dr-joseph-tucker-provides-2021-year-in-review-and-2022-outlook-in-letter-to-shareholders-301462479.html

SOURCE Enveric Biosciences